Introduction
Obesity is a worldwide epidemic, costing billions of health care dollars in cardiovascular disease, diabetes, hypertension, etc. In the area of cancer, obesity, which is usually associated with a high fat diet, has been associated with several tumors. 1 Obesity is measured as body mass index (BMI). BMI is defined as the weight in kilograms over the height in meters squared (kg/m 2 ). BMI has been used as a relative standard for insurance companies, health institutions, and scientific data collection. A BMI under 25 kg/m 2 is considered normal weight, whereas a BMI between 25 and 30 kg/m 2 is considered overweight. A BMI over 30 kg/m 2 is considered obese. [1] [2] [3] [4] [5] [6] [7] [8] Prostate cancer is the leading cause of male cancer in the United States. There will be 186 000 new cases of this disease diagnosed in the United States this year, and there will be 40 000 deaths. While there are significant differences in the incidence of prostate cancer among different ethnic groups, the prevalence of microscopic, incidental prostate cancer in young men of different ethnic groups is similar worldwide. 9 This was demonstrated in autopsies of young men who died in battle. 9 Since we see a dramatic change in the incidence of clinically significant prostate cancer in the fourth, fifth sixth and seventh decades, other parameters must play a role for the variations seen. 9 Numerous reports have demonstrated strong associations between a high fat diet and prostate cancer. However, we wanted to investigate if obesity alone, independent of diet, may also play a role. Several studies have demonstrated using the measurement of several growth factors as a barometer of tumor progression. [10] [11] [12] [13] [14] Since adipose tissues may act as a reservoir for some growth factors, as well as may impair the immune system, [16] [17] [18] [19] [20] [21] we analyzed these parameters in our rodent model in order to determine if any differences may exist between lean and obese animals.
Materials and methods
Our method of fibroblast growth factor (FGF-2) and vascular endothelial cell growth factor (VEGF) quantitation was through the use of ELISA plates from R&D Inc. as per the manufacturer's instructions. Using the color chart included and using purified FGF-2 and VEGF as controls, we compared FGF-2 and VEGF concentrations in lean and obese Zucker rat sera.
Our assay to determine macrophage activity was purchased from PeproTech Inc. This assay utilizes recombinant rat macrophage inflammatory protein-1 alpha (MIP-1a), an antigen affinity purified polyclonal antibody, as per the manufacturer's instructions. Our controls were built into the ELISA kit.
Rat sera were obtained from Charles Rivers Labs. All rats were female 6-month-old lean (280-320 g, Fa/Fa, Fa/fa) and obese (610-650 g, fa/fa, 450% BMI than lean) Zuckers and fed on equal amounts of low fat rat chow. BMI was determined by the length and weight of the rat and determining fat content through dual energy X-ray absorptiometry (DEXA) scanning. The higher weight and BMI in obese Zucker rats is due a mutation in the leptin receptor. The sera were always collected in the morning. For the FGF/VEGF assays, we used three samples each from three lean and three obese rat sera samples (n ¼ 18).
For the MIP-1a assays, we tested three samples each of three controls, three lean and three obese sera, for a total of 27 assays. For mitogenicity we used the prostate cancer cell line LNCaP using the MTT assay. This technique quantitates the number of mitochondria in the field by immunohistochemistry, which correlates with cell count.
The LNCaP cells were grown in RPMI medium supplemented with 10% FBS until in active growth phase and then 0.4% FBS to bring them to a quiescent state. They were then plated on 12-well plastic plates in concentrations of 10 000 cells/cm 3 on day one and 1 incubated at 371C and 5% CO 2 . Cells were refed with 0.1% FCS to achieve a quiescent state on day 2, and on day 3, 50 ml. of each sera fraction are added to the well in triplicate. Following incubation with a sample of sera the cells were washed twice with Hanks' balanced salt solution. Counts were performed by a Zeiss stereotopic microscope using scanning computer software to measure the concentration of stained mitochondria. For dose response experiments, tumor cells were exposed to varying concentrations of sera from lean and obese Zucker rats using a dose-response curve.
Average counts per ELISA and culture assays were analyzed using w 2 methods and ANOVA. Differences were considered significant if the level of chance occurrence is o0.05. Based on the hypothesized difference of 20% increase in proliferation, a sample of 60 cultures (in triplicate) was required to provide 80% power to detect the hypothesized difference with a 5% type 1 error based on a two-tailed analysis.
Results
The data demonstrated that sera from obese Zucker rats had a greater concentration of FGF-2 than sera from lean rats: 6.3270.56 vs 3.4870.34 pg/ml, respectively, Po 0.05. We also determined a difference in the concentration of serum VEGF between obese and lean Zucker rats: 54.474.1 vs 38.0072.9 pg/ml, respectively, Po0.05. Table 1 demonstrates the FGF-2 and VEGF concentrations between obese and lean Zucker rat sera, respectively.
We also detected a trend in greater mitogenic stimulation from obese rodent sera compared to lean rodent sera on LNCaP cells on the higher concentrations of the doseresponse curve: 0.7270.06 compared to 0.5170.05, respectively. However, this was not statistically significant.
We found no significant differences in macrophage function between lean and obese rat sera using the MIP-1a assay. Implications in obesity-related tumor biology JH Mydlo et al
Discussion
Although the prostate is clearly a sex steroid-dependent tissue, growth factors and other cytokines play an important role in the development and progression of several cancers. [10] [11] [12] [13] In certain cases of aberrant prostate growth, the growth factors may be overproduced or the receptors may be overexpressed, or both.
12 Basic fibroblast growth factor, or FGF-2, is one of the predominant angiogenic growth factors present in prostate tissue, and deemed to play an important role in the development of stroma cells, epithelial cells, and neoplasia. In a previous report, we had isolated FGF-2 from both benign prostatic hyperplastic tissue (BPH) as well as from prostate cancer tissue (CaP). 12 Since FGF-2 also induces neovascularity, or angiogenesis, we explored the role of FGF-2 specifically in prostate tumor biology. 5, 12 Angiogenesis is a significant precursor prior the growth and invasion of most tumors, including the prostate. 13 We demonstrated a greater angiogenic activity of FGF-2 in fatty adipose tissue compared to prostate tissues. This was first done using the rabbit cornea model, followed by the chick chorioallantoic membrane (CAM) assay. 5, 12, 14 In another report, we have shown that adipose tissue expressed more growth factor activity than either benign prostatic hypertrophy or cancerous prostatic tissues, suggesting that adipose stores may harbor increased growth factor activity that may stimulate prostate tumors. 5 Several reports have shown the benefit of a low fat diet on prostate cancer. Nude mice fed on low fat diets had slower progression of implanted prostate tumors than on high fat diets. 8 Other reports have demonstrated the decrease of PSA in men with prostate cancer who started on low fat diets, and on those patients who started exercising and had less stress. 4 Longitudinal studies have demonstrated that breast cancer patients with a higher BMI had a greater chance of tumor progression than leaner patients. 2 Although there has been evidence associating a high fat diet to prostate cancer, there is controversy over the effects of obesity alone on prostate cancer.
It is difficult to separate the effects of diet from BMI, since the two are very closely intertwined. Therefore, using a genetic model such as Zucker rats, who maintain either an increased BMI or lean BMI irrespective of their diet, may answer this question. However, the factors affecting prostate cancer are multiple: genetics, increased growth factor and/or testosterone reservoirs, tumor vascularity, aging effects on the immune system impairing natural killer cells causing increased free radicals, etc. [15] [16] [17] [18] [19] [20] [21] Therefore, obesity may play just one role. Weber et al 6 demonstrated a greater progression of pulmonary metastases in obese Zucker rats induced with colon cancer than in lean Zucker rats, both of which were on low fat diet. We reported more aggressive prostate tumors with higher stages in patients who underwent radical prostatectomies who had a greater BMI than leaner patients. 7 From these data, we speculated that obesity alone, independent of diet, may have its own effect on prostate tumor progression.
In the present report, we analyzed the sera of lean and obese Zucker rats to test for differences in levels of VEGF and FGF-2 concentrations. We speculate that the higher levels of both FGF-2 and VEGF in the sera of obese Zucker rats compared to lean Zucker rats, two growth factors that are intimately involved in the growth of prostate cancer, may be extrapolated to the human condition. However, the finding of no differences in immune function nor significant differences in mitogenic activity on plated cells, suggests that other mechanisms may play a role in obesity-related tumor biology. Therefore, although a high fat diet, as well as obesity, may play a synergistic role in the progression of prostate cancer, it may be through other routes.
A limitation of this study is that only FGF-2 and VEGF levels were analyzed. Certainly, many other growth factors exist that may also play a role in prostate cancer biology. Also, the lack of in vitro and/ or in vivo experiments with FGF-2 and VEGF directly on the prostate does not answer the question of obesityrelated tumor biology. Therefore, although we found increased levels of these factors in obese Zucker rat sera compared to lean, we still have yet to demonstrate the significance of this.
We realize that this study is based on a small sample of sera. In addition, there are numerous other substances and mechanisms present in sera that may play a role in tumor development. Furthermore, we only evaluated FGF-2 and VEGF levels from female rat sera, and did not evaluate male rat or human sera. Moreover, we only speculate that rat sera growth factors may affect human prostate cancer cells in vitro, but this has not been proven. The fact that we did not demonstrate a significant difference of mitogenicity also makes these data difficult to extrapolate to the human condition. Although we only used sera collected in the morning, we do not know what effects circadian fluctuations may have, as well as variability within an animal may have. Furthermore, the models used may not have the responsitivity to these factors that is found in abnormal human growth, However, based on these preliminary findings, as well as our previously published work that complements these results, 5, 7 we believe that increased BMI in animals amounts to additional adipose tissue reservoirs that contain certain growth factors. This can affect sera levels and therefore may play a role in prostate cancer progression.
Future experiments will need to be conducted to corroborate or refute this hypothesis. Further studies examining male rat as well as human sera, and examining other growth factors such as transforming growth factor alpha or beta (TGFa or TGFb) will be considered. Future experiments will also utilize other cell lines such as PC-3 and MatLyLu, and explore sera effects on umbilical vein endothelial cells (HUVEC) to determine angiogenic effects. Lastly, we will explore other methods of assessing immune status such as utilizing the cytotoxic T cell assay, and will compare both male and female sera.
In conclusion, this is a preliminary report demonstrating a greater concentration of VEGF and FGF-2 serum levels in obese vs lean Zucker rats. However, we found no significant differences in macrophage function, or mitogenic response on LNCaP prostate cancer cells. We speculate that although increased BMI index in humans may lead to elevations of certain growth factors, and/or impaired immune function, both of which may affect tumor biology, there may be many other mechanisms that play a role in obesity related prostate tumor biology. While tumor growth is based on multifactorial effects, 
